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ABSTRACT OF THESIS
Nanomaterials and Block Copolymers for Overcoming Multidrug Resistance in Cancer
by
Wesley Livingston
Master of Science, Graduate Program in Biochemistry
Loma Linda University, June 2011
Dr. Christopher Perry, Chairperson

The development of multidrug resistance in cancer is one of the leading
causes for decreased chemotherapy efficacy and is particularly threatening to
aggressive cancers such as that of the pancreas. In cancers where chemotherapy is
amongst the few treatment options, it is crucial to develop chemotherapeutics that
either bypass or control the development of multidrug resistance. Polymeric
nanomaterials such as Pluronics® are of current interest due to their ability to
perform these functions in addition to enhancing pro-apoptotic mechanisms.
Using the respectively known chemosensitive and chemoresistant pancreatic
adenocarcinoma cell lines MiaPaCa-2 and PANC-1, an in vitro analysis of the
synergistic effect using 5-fluorouracil in conjugation with Pluronic® F127 was
performed. By monitoring cell viability and regulation of cell cycle, we were able
to show that compared to the use of 5-flurouracil alone, there was enhanced
cytotoxicity when using drug associated with Pluronic® F127 in MiaPaCa-2 cells.
The more chemoresistant cell line PANC-1 showed no significant enhancement of
5-fluorouracil cytotoxicity when associated with Pluronic® F127. Enhanced
cytotoxicity due to the use of Pluronic® F127 may potentially become an
exploitable feature for novel chemotherapeutic development in the future.

xi

CHAPTER ONE
INTRODUCTION

Hurtles in Chemotherapy Efficacy and Development
A malignant neoplasm is generally defined as a group of cells that have acquired
uncontrollable cell growth through the stimulation of their cell cycle [1]. Furthermore,
these cells have developed methods towards evasion of cell death, stimulation of
angiogenesis, and invasion of tissues through metastasis [1-2]. Chemotherapeutic agents
work to stimulate alternative mechanisms of cell death in these neoplastic cells while
maintaining minimal collateral damage of non-neoplastic cells. Therefore, the ideal
chemotherapeutic would be equally potent and target specific. However, there are
multiple pharmacokinetic and pharmacodynamic considerations when optimizing the
function and efficacy of a particular chemotherapeutic.
Pharmacokinetics (what the body does to the drug) is defined as the absorption,
distribution, metabolism, and secretion of a drug from a physiological system while the
pharmacodynamics (what the drug does to the body) is defined as the biochemical
influence of a drug on a physiological system and its mechanism of action [3]. Although,
the efficacy of a chemotherapeutic depends on several factors, in a chemotherapy patient,
it is the pharmacokinetics that affects the pharmacodynamic functions of the drug. For
instance, even if a particular novel drug candidate shows excellent pharmacodynamic
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properties in vitro, in vivo it may have poor solubility in the physiological environment,
and therefore poor circulatory bioavailability.
A researcher must consider the many pharmacokinetic characteristics of a drug when
attempting to develop new or improved chemotherapeutic agents. First, it is important to
consider the absorption and distribution of the drug in an in vivo model. The absorption
and distribution of drug in the blood stream are dependent on several factors but none so
much as that of drug solubility [3-4]. For instance, Aspirin is insoluble in the acidic pH of
the digestive juices in the stomach. However, when the drug enters the lumen of the small
intestine, it is solubilized by the neutral and alkaline aqueous environment. Therefore, the
rate of dissolution is the dependent step of drug absorption through the lumen of the
small intestine and into the circulatory system [3]. The amount of drug that actually
reaches the circulatory system from the gastrointestinal tract must then pass through the
portal vein and into the liver before it is able to be distributed in the systemic circulation.
The liver is the main organ responsible for the cleansing of the components of the
circulatory system. Relative to drugs, the liver is involved in the metabolism or
biotransformation of a drug into a more soluble, inactive, or even more active forms.
Although there exist several ways to optimize both the pharmacokinetic and
pharmacodynamic specifications of chemotherapeutics, there are still several cellular
defensive mechanisms that may avoid the pharmacodynamics of a chemotherapeutic
agent. Cells that are able to mediate this pharmacodynamic evasion are termed drugresistant or multidrug resistant if this pharmacodynamic evasion occurs with a variety of
chemotherapeutics.
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Decreasing Chemotherapy Efficacy via Multidrug Resistance
Multidrug resistance is one of the leading causes for modern chemotherapy failure and
is of particular importance in cancers where chemotherapy is amongst one of the few
ways to manage the cancer. Multidrug resistance is characterized by the ability to avoid
the cytotoxic effects of a particular drug and is caused by several factors. For example, a
chemotherapeutic may initially kill those cells that are particularly sensitive to the
chemotherapeutic agent, leaving behind cells that may have a resistance to the drug. Over
time, when the cancerous cells have grown back to a detectable amount, the majority
contains the similar drug-resistant factors that contributed to the lack of chemotherapeutic
potency in the primary treatment. Therefore, when the chemotherapeutic is reintroduced,
or even if it had been administered over a continuous and prolonged period, the cancer
appears to respond less.
Another mechanism towards cellular multidrug resistance is through the expression of
drug efflux pumps such as the P-glycoprotein (Pgp) and multidrug resistant protein
(MRP) [5-6]. These ATPase drug efflux pumps are responsible for expelling
chemotherapeutic drugs from within the cell before they are able to reach their target.
Although these drug efflux pumps may be beneficial to cancer cell survival, they may
also be found in normal cells. For example, cells in the liver, gastrointestal gland, and the
renal tubules of the kidney highly express Pgp pumps which expel small molecules
across their cellular membranes. However, when they are expressed in cancerous cells,
they gain the potential ability to expel the chemotherapeutic.
The expression of these drug efflux pumps has been shown to correlate with the extent
of drug resistance. For instance, using selective DNA transfer from a drug-resistant cell

3

line that expressed Pgp pumps into a cell line that was not drug-resistant, the DNA
recipient gained a degree of drug resistance due to Pgp gene expression [5, 7]. A similar
approach was used to show that expression of MRP in lung cells was correlated with drug
resistance [5]. As a result, there are many pharmaceutical companies that have formulated
drugs that target the function and/or expression of these drug-resistant proteins. For
example, Vertex has produced Incel which blocks both Pgp and MRP in vitro, and
thereby restores tumor chemotherapy sensitivity by increasing drug concentration within
the cell [5]. However, normal cells also express these drug efflux pumps and are
necessary for maintaining physiological homeostasis.
Since the drug-resistant proteins have been shown to correlate to drug resistance, it
has been postulated that the inducible resistance through factors such as DNA transfer
can become beneficial to cells that were not targets of the drug. More specifically,
chemotherapy often targets rapidly replicating and differentiating cell lines (such as those
of involved in hematopoiesis) which may or may not require the regulation of
chemotherapeutic doses in order to allow for their restoration. If the drug-resistant
properties given by these drug efflux pumps can be inducible into these hematopoietic
cells, the negative side effects seen in many chemotherapy patients will be reduced. Titan
Pharmaceuticals have already undertaken this idea in their creation of MDRx1 which can
induce multidrug resistance in blood progenitor stem cells after Pgp gene insertion [5].

Nanomaterials and Pluronics®: Improving Drug Delivery
Overall, increasingly efficacious chemotherapeutics must mediate their biochemical
influence with potency, accuracy, and with aversion towards the development of
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multidrug resistance; although they themselves are not the effecter compound,
nanomaterials are beginning to show promise in being able to assist chemotherapeutics
towards this goal. The reason why nanomaterials are currently making their way into the
clinical realm of pharmacology is due to their many unique pharmacokinetic and
pharmacodynamic properties. Some of the main nanomaterials of clinical interest are
gold nanoparticles, liposomes, and nanomaterial based surfactants [8]. Together with
their drug they behave as drug carriers, increasing both drug potency and accuracy.
Gold nanoparticles are inert and nontoxic gold particles surrounded by an organic or
biomolecular monolayer, allowing for the conjugation of targeting ligands and drugs [810]. As such, gold nanoparticles can be constructed to increase the pharmacokinetic
characteristics of a particular drug. Furthermore, gold nanoparticles contain unique
photochemical characteristics that allow for the controlled physical manipulation of their
shape and size [11]. For example, it has been shown that upon near-infrared laser
radiation of engineered hybrid polymeric gold nanoparticle drug capsules, there was an
alteration in the particle shape, capsule rupture, and drug release at a specific site [12].
Similar controlled drug release mechanisms have been shown to work for DNA [13].
Liposomes are also capable of performing similar functions. Liposomes are phospholipid
bilayer vesicles capable of encapsulating cargo within its interior. Hence, liposomes have
been used as drug delivery vehicles for both hydrophilic and hydrophobic drugs. Not only
are liposomes inert, biocompatible, nontoxic, and able to avoid immune responses, they
can also be mass produced in the pharmaceutical industry [14-16]. Like gold
nanoparticles, they are also able to become functionalized with targeting ligands that may
increase tissue specificity. For instance, customization of membrane lipid composition
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and charge of the liposomes allows for the increased drug uptake across physiological
barriers such as that in the brain. A class of nanomaterial based surfactants called
Pluronics® work in a similar way to liposomes in that they are able to act as drug carriers,
improving pharmacokinetics and biodistribution of particular drugs [17].
Pluronics (PL) are a class of self associating, amphiphilic, tri-block copolymers with
hydrophilic ethylene oxide (EO) and hydrophobic propylene oxide (PO) blocks and like
the other nanomaterials discussed, they are able to be functionalized to improve their
target efficacy. In polar solvents, they self associate into micelles at various
concentrations based on their engineered chain composition and length, defining the
degree of their amphiphilicity. As a result of their amphiphilicity, at high enough
concentrations, the polymer unimers self-associate into micelles which contain both a
hydrophilic and hydrophobic regions. The concentration at which this occurs is called the
critical micelle concentration (cmc) and has been shown to be dependent on temperature
[18-20]. This unique characteristic has been utilized to solubilize and transport
hydrophobic drugs within the hydrophobic core of the PL micelles. For example, Kwon
and others used in vitro and in vivo studies that showed increased solubility and
bioavailability of the water insoluble drug genistein when encapsulated in PL F127 [21].
PLs have also been shown to increase the biodistribution of water soluble drugs. For
example, through in vitro and in vivo experiments, Valle and others shown that the
pharmacokinetics and biodistribution of doxorubicin increases when encapsulated in a
formulation of PL L61 and F127 [22].
In addition to being good candidates for drug delivery systems, PLs are also being
evaluated for their ability to exhibit synergistic effects along with their cargo drug,
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avoiding multidrug resistant pathways [17]. For example, Kabanov and others have
determined that the formation of micelles decreased the uptake of these tri-block
copolymers in the liver without affecting total clearance in the kidney [17]. As a result,
oral admissions of PL/drug conjugates are better able to avoid metabolic biotransformation and/or deactivation in the liver while later avoiding the side affects
associated with low clearance rate of the drug [17]. PLs are also believed to be able to
alter the microviscosity of tumor membranes and their surrounding vasculature, further
increasing their already high permeability, making them of increasing interest in
chemotherapeutics. Given that membrane protein stability and conformation are largely
dependent on membrane integrity, the features of PL could also be used to show
membrane protein inhibition [23-27]. Using FRET analysis of PL P85 concentrations
below their cmc, it was shown that the P85 unimers largely associated with the lipid rafts
of Pgp efflux pumps. Enzyme kinetics then showed decreased activity of the pumps along
with decreased ATP levels [17]. Since, MRP efflux pumps are not associated with lipid
rafts, there was little effect observed. PL P85 and other PL unimers have also been shown
to affect cellular respiration by trans-locating into the mitochondria [16-17]. Here, they
disrupt mitochondria membrane activity, leading to the downstream inhibition of the
electron transport chain and ATP synthase [17, 25-31]. Furthermore, it has been shown
that use of a doxorubicin/PL P85 conjugate significantly increases pro-apoptotic genes as
compared to the use of doxorubicin alone; one possible explanation being the
accumulation and release of Cyt c. [32].
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Need for Alternative Adjuvant Therapy for a Particularly Lethal
Cancer
As of the 2010 cancer statistics published in the journal CA: A Cancer Journal for
Clinicians, A poll taken in 2007 shows cancer as the second most leading cause of death
in the United States [33]. A comparison of those cancer related deaths showed that
among the more common lethal cancers such as lung and bronchus, stomach, colon and
rectum, prostate, uterus, ovary, breast, pancreas, leukemia, and liver cancers, cancer of
pancreas remains the 4th most common cause of cancer related death in males and
females [33]. Furthermore, the data suggests little decrease in pancreatic cancer death rate
since 1930 [33].
Pancreatic cancer spreads quickly to the adjacent tissues such as the neural tissue,
duodenum, portal vein (drains blood from the gastrointestinal tract and spleen to the
liver), superior mesenteric vein (drains blood from the small intestine and terminates
behind the pancreas where it merges with the splenic vein to form the portal vein), and
regional lymph nodes. When localized in the pancreas, there are several resection options
depending on the location of the primary tumor and degree of metastasis. For example,
when the tumor is localized in the head of the pancreas, pancreatoduodenectomy (PD),
subtotal stomach-preserving pancreatoduodenectomy (SSPPD), or pylorus-preserving
pancreatoduodenectomy (PPPD) are performed [34-36]. Likewise, when the tumor is
localized in the body and tail of the pancreas, distal pancreatectomy (DP) with
splenectomy is performed. When the tumor is localized in the head of the pancreas, PD is
preferred above the other types of resection methods. However, surgery alone does not
appear to notably increase survival rate of patients. It is therefore recommended that
patients also go through chemotherapy or chemoradiotherapy [36].
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Currently, chemotherapy and chemoradiotherapy are preferred over radiotherapy
alone. This is because although radiotherapy is able to reduce the recurrence rate, it does
not significantly increase the survival rate. Chemotherapy and chemoradiotherapy on the
other hand do appear to provide a benefit to the overall survival rate in patients who have
had resection of the primary tumor. Orthodox chemotherapeutics include gemcitabine
and 5-fluorouracil (5FU) which mainly alleviate disease related symptoms such as pain.
However, their use does not significantly increase the survival rate and therefore brings
into question the apparently ambiguous affect on survival [36].
Nevertheless, pancreatic cancer is particularly lethal due to its aggressive nature,
relatively late onset of symptoms, and has an average life expectancy of 5 years after
diagnosis. On average, 85%-90% of patients are diagnosed with locally advanced
unresectable or metastatic stages of the cancer. Even for the patients who are able to
undergo curative resection (10%-20%), only 10%-20% of them actually survive 5 years
post diagnosis [36-41]. Hence, only about 5% of patients diagnosed with pancreatic
cancer actually reach the 5 year life expectancy [42-43]. Although a patient may have
curative resection of the cancer, the median survival rate for these patients is similar to
that for patients with unresectable nonmetastatic pancreatic cancer. Given these facts,
more innovative and efficacious detection and treatment methods need to be developed.

Proliferation of Non-neoplasic Cells, Neoplastic Cells,
and the Biochemical Role of Chemotherapeutics
Contributing the aggressiveness of pancreatic cancers to any set of factors such as
genotype and phenotype is difficult [44-46]. However, what is common between the vast
majorities of pancreatic adenocarcinoma cell lines is their loss of cell cycle regulation.
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Excluding gamete cells, normal non-neoplastic cells replicate from the consecutive cell
cycle process of cell interphase and mitosis (Figure 1). Interphase itself is divided into
three sub-stages: G1, S, and G2. After a mitotic division of a cell, it enters the first phase
of interphase called G1. Here, the cell matures and awaits growth signals or favorable
environmental conditions in which it is appropriate for another round of cell division.
Given desirable conditions, the cell may then begin to replicate its DNA. This phase of
the cell cycle is called the S-phase and commits the cell to finish replication. Upon
replication of cellular DNA, the cell enters the last phase of interphase called the G2phase. Here, the cell makes preparations for mitosis such as producing the microtubules
necessary for arranging and separating homologous chromosomes during the mitotic
phase (M). Cell cycle phase checkpoints ensure the series of events and performed both
efficiently and with fidelity. If these cell phase checkpoints encounter problems that
significantly effect the parent and/or daughter cells, the cell cycle is arrested in that
particular phase of the cell cycle.
The process of cell division is largely dependent on a class of proteins called cyclindependent kinases (Cdk) that when activated by their cyclin, promote the transcription of
genes necessary for the stages of the cell cycle [1, 47]. In each cell, there are four known
classes of cyclins, each defined by their Cdk at individual stages of the cell cycle. For
instance, in non-neoplastic cells, favorable conditions lead to the activation of G1-Cdk
during the G1-phase of the cell cycle. When activated, it is capable of promoting the
transcription of G1/S-cyclins, which then activate G1/S-Cdk. Upon its activation, G1 ends
and the cell becomes committed to initiate DNA replication. S-cyclins are also produced
in the G1-phase which is necessary for the activation of S-Cdk in the S-phase where DNA
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M-Cdk:
Cyclin: B
Cyclin Partner: Cdk1
Unfavorable replication conditions

M

G1-Cdk:
Cyclin: D1, 2, 3
Cyclin Partner: Cdk4, Cdk6

G2

11

Excess mitogenic stimulation
S-Cdk:
Cyclin: A
Cyclin Partner: Cdk2

S

G1
DNA damage
G1/S-Cdk:
Cyclin: E
Cyclin Partner: Cdk2

Figure 1. Phases of the cell cycle and their respective cyclins and cyclin partners. Also included are a
few representative cell cycle checkpoints capable of inducing cell cycle phase arrest (as represented
by lines ending perpendicularly).

replication occurs. Finally, Inhibition of DNA replication, initiation of the G2-phase, and
progress through the ending stages of mitosis is directed by M-Cdk and its protein
counterparts. M-cyclins produced during between the G2 and M phase help support their
activity.
The processes in the cell cycle contain several complex, and sometimes antagonistic,
regulatory components in order to maintain order, necessity, and quality in cell division;
the following are only able to show an over simplified description of these regulatory
mechanisms and are summarized in Figure 2. For example, the activity of Cdks
throughout the cell cycle may become modified through phosphorylation by kinases such
as Wee1 and Cdc25 phosphatase [47]. Other regulatory proteins are capable of either
directly binding to and inactivating their targets or causing their downstream degradation.
For example, in the G1-phase of the cell cycle, a Cdk inhibitory protein p27 directly binds
to and inactivates G1/S-Cdk and S-Cdk [47]. In the G1 and S phase there also exists
ubiquitin ligases such as Skp, Cullin, F-box containing complex (SCF). Guided by
phosphorylated targets throughout the cell cycle, SCF leads to the degradation of certain
Cdk inhibitory proteins and G1/S-cyclins that control S-phase initiation [48-50]. Other
ubiquitin ligases such as the anaphase-promoting complex (APC) lead to the downstream
degradation of M-cylins and other mitotic regulators [51-52]. Its own activity varies at
different stages of the cell cycle. Mutations in such regulators are the hallmarks for
various types of cancers.
Gene regulation of components necessary for cell cycle progression is another way
that non-neoplastic cells regulate their cell cycle. For instance, the gene regulatory gene
E2F is responsible for the activation of promoters that encode for proteins required for S-
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phase entry such as the G1/S-cyclins and S-cyclins [53]. However, during the G1-phase,
the E2F regulatory retinoblastoma protein (Rb) binds to E2F, inhibiting its activity. Also
inhibited in the G1-phase is Cyclin D of G1-Cdk by the Cdk inhibitory protein p16INK4A
[1, 6, 54-55]. It is not until the favorable environment and/or proper growth signals does
the G1-cyclin become activated by Cyclin-D [56]. When this occurs, the activated G1-Cdk
phosphorylates Rb, inactivating it, and releasing active E2F. Relative to pancreatic
adenocarcinoma, mutated p16INK4A is one of three commonly mutated cell cycle
mediators in 90% of cell lines; mutated Ras and p53 being the other two [46, 54-55].
However, E2F activity is also regulated through the activation of another gene
regulatory protein called Myc which is the downstream product of MAP-kinase
activation [57]. This process begins though the activation of a membrane bound GTPase
Ras protein. Specifically, mitogen growth factors stimulate the activation of Ras upon
which it binds GTP, becoming active, and mediating the phosphorylation of MAP-kinase.
By unknown mechanisms, MAP-kinase is able to activate gene regulatory proteins that
are involved in the downstream transcription of genes such as Myc [47]. Myc itself
mediates the transcription of cellular proliferation proteins such as Cyclin-D. As a result,
Cyclin-D activates G1-cyclin, which stimulates Rb phosphorylation and so forth. Myc
also regulates E2F transcription factors and SCF protein subunits [2]. Since increased
SCF increases p27 degradation, there is increased G1/S-Cdk activation. Mutations in the
Ras protein, as seen in the majority of pancreatic adenocarcinoma cell lines, may lead to
hyperactivity of the protein and therefore increased cell signals in favor of replication.
There are also means of regulating the effects of abnormal proliferation signals and
DNA integrity after replication; p53 is the most known tumor suppressor gene
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responsible for that purpose and is also mutated in the majority of pancreatic
adenocarcinoma cell lines [2, 46, 54-55]. Normally, unphosphorylated p53 is bound to
Mdm2 protein and is targeted for ubiquitination [58-59]. If phosphorylated, p53 and
Mdm2 dissociate and it is able to transcribe Cdk inhibitory genes and mediate apoptotic
pathways or cell arrest [60-61]. For example, high amounts of Myc often leads to the
production of another cell cycle inhibitor protein called p19ARF [47]. This inhibitor
protein is capable of binding to Mdm2, releasing p53, and allowing it to promote genes
involved in apoptosis or cell arrest [62]. p53 also is present in the response to DNA
damage. This is largely due to a series of cell cycle checkpoints that are activated by
protein kinases in the presence of mechanical errors in cell cycle. For example, in the
response to DNA damage, cell cycle checkpoint protein kinases decrease p53 affinity to
Mdm2 through phosphorylation of p53 [63-64]. This activated p53 is then able to bind to
promoters of genes that encode for Cdk inhibitor proteins such as p21, capable of
inhibiting the cyclins and Cdk partners of the G1-Cdk complex [2].
The goal of chemotherapeutics is to compensate for the defective components of a
cancerous target's cell cycle physiology. Chemotherapeutic agents work optimally when
stimulating cell death pathways in their target tissues while maintaining minimal
collateral damage of non-neoplastic cells. There are two main processes of cell death:
necrosis and apoptosis. Necrosis is often caused through traumatic injury to a cell,
causing it to lyse and cause inflammation. Furthermore, the often digestive lysate of lysed
cells may cause collateral damage to adjacent cells.
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Figure 2. Summary of cell cycle regulatory mechanisms. Placement of text shows the relative phase of the
cell cycle where the particular regulatory pathway is found. Arrows represent "activation by" while lines
ending perpendicularly represent "inhibited by." Text in bold represent the mutations found in the majority
of pancreatic adenocarcinoma cell lines

In contrast to necrosis, apoptosis is the process of programmed and controllable cell
death. Apoptosis functions through the use of cysteine proteases and unlike necrosis, it
has many important physiological roles in maintaining homeostatic balance. For example,
apoptosis is responsible for the elimination of old, unnecessary, or damaged cells under
non-inflammatory conditions [1-2]. Apoptosis is also responsible for the maintenance of
physiological homeostasis and embryonic anatomical development [2]. For example,
apoptosis is responsible for the regulation of immune cells and the cells contributing to
organ, tissue architecture, and bone development.
There are two main paths towards apoptosis: extrinsic and intrinsic signaling
pathways. The extrinsic signaling pathway, or the death receptor mediated pathway
involves the interaction of a death receptor with its ligand; two particular ligands capable
of initiating the extrinsic signaling pathway are Fas ligand and TNF-α [65-66]. When the
ligand comes into contact with the death receptor, FADD and procaspase-8 and -10 are
recruited to the intracellular domain of the receptor, forming the death inducing signaling
complex (DISC) [65-66]. This complex is capable of activating procaspase-8, which in
turn is able to cleave and activate executioner caspases such as caspases-3, -6, and -7 [6566]. It is the executioner caspases that are able to induce cellular apoptosis.
The intrinsic signaling pathway does not require extracellular mediated activation of
apoptosis; it is able to initiate apoptosis through intracellular signals such as cellular
stress or DNA damage. Upon one of these intrinsic signals, there is a perturbation in the
genetic expression of pro and anti-apoptotic proteins such as BAX and BCL-2
respectively. When there is sufficient expression of the pro-apoptotic protein, the
mitochondrial membrane begins to leak Cyt c and other apoptotic regulators that support
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the apoptotic cascade [67]. The secretion of Cyt c itself leads to its aggregation with
Apaf-1 and procaspase-9, forming the apoptosome which serves to activate procaspase-9
into the initiator caspase-9 [67]. Caspase-9 is then able to activate the executioner
caspases-3, -6, and -7 which lead towards apoptosis.

Purpose of this Study
As mentioned previously, 5FU is used to treat pancreatic cancer but does not
significantly increase the survival rate of patients. 5FU itself is an antimetabolite uracil
analogue that is able to exhibit anticancer effects through incorporation into RNA and
DNA. As a result, proper cell division and protein synthesis is affected due to
misincorporation of the active cytotoxic metabolites of 5FU. The metabolism of 5FU
occurs inside the cell. However, nearly 80% of 5FU is metabolized in the liver [68].
Here, dihydropyrimidine dehydrogenase (DPD) metabolizes 5FU into the inactive form
called dihydrofluorouracil (DHFU) [69]. DPD is also found in other cells but at much
lower concentrations. The fraction of 5FU that is not transformed into DHFU is
converted into the active cytotoxic metabolites.
The overall ineffectiveness of 5FU in the treatment of pancreatic cancer may be
described by the carcinoma's resistance to the drug itself. For instance, it has been shown
that there is overexpresion of the multidrug resistance associated protein MRP5 in the
two pancreatic adenocarcinoma cell lines PANC-1 and MiaPaCa-2 [70-71]. Furthermore,
this protein has been shown to actively confer drug resistance towards 5FU in pancreatic
adenocarcinoma and other cancerous cell lines [26, 71]. Research has also shown that
PLs are capable of reducing these pumps along with other mechanisms that lead to poor
drug effectiveness. The central hypothesis of this work is that by using these PLs as drug
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carriers, the innate pharmacokinetic obstacles in target cells will be reduced or entirely
evaded. Furthermore, by using these conjugates it is hypothesized that there will be
observable and measurable phenotypic effects in target cells. This study explores these
observable effects in the pancreatic adenocarcinoma cells lines PANC-1 and MiaPaCa-2.
Cell viability experiments using alamarBlue® were performed in order to monitor any
synergistic effect between PL and its drug. Any effect on cell cycle is monitored by flow
cytometry. Microscopy was also used to visualize any phenotypic changes in cell
viability.
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CHAPTER 2
MATERIALS AND METHODS

Materials
PL F127 was purchased from Sigma-Aldrich (St. Louis, MO). 5-flourouracil (99.0%
purity), propidium iodide (PI), and 0.25% trypsin with 1mM EDTA without Ca2+ or
Mg2+, and in balanced salt solution in modified Hanks’ were obtained from MP
Biomedicals (Solon, OH). Ribonuclease A (RNase) was obtained from Fisher
BioReagents (Fair Lawn, NJ). Fetal bovine serum (FBS), penicillin-streptomycin
antibiotic solution, Hanks’ balanced salt solution (HBSS)/modified, without Ca2+ or Mg2+
and Dulbecco’s modified eagles medium (DMEM)/high glucose with 4.00 mM Lglutamine 4500 mg/L glucose, and sodium pyruvate were purchased from Thermo
Scientific HyClone (Logan, UT). Ethanol (purity 95.0%) was purchased from Acros
Organics (Morris Plains, NJ). alamarBlue® was purchased from AbD Serotec (Oxford,
UK). DMEM with L-glutamine and the pancreatic cancer cell lines MiaPaCa-2 and
PANC-1 were obtained from ATCC (Manassas, VA). All phosphate buffered saline
(PBS) solutions were prepared from powdered PBS, pH 7.4, and dissolved in ultra pure
water from a Barnstead Nanopure Diamond purifier.

Characterization of PL F127
The physical characteristics of PL F127 in solution where determined by fluorescence
spectroscopy and a pyrene (99.0% purity) probe from Sigma-Aldrich (St. Louis, MO). A
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7.2 µM pyrene solution was prepared from acetone and 333.0 µL of this solution was
added to 40 5 mL glass vials. The acetone from these vials was allowed to evaporate
overnight and 4 mL of different PL F127 concentrations were added to each, making 0.6
µM pyrene in each vial. The PL F127 solutions added to these vials ranged from
0.0001% to 20% (w/v) and were made from a 20% PL F127 stock solution in 10 mM
PBS. Samples were incubated for at both 25°C and 37°C for at least 7 hrs prior to
analysis.
A Photon Technology International Model T PTI spectrofluorometer (Brimingham,
NJ) with a magnetic micro-stirrer and Peltier temperature regulator was used for all
fluorescence measurements. The lamp, excitation, emission, and PMT slits were set at
0.30, 0.20, 1.00, and 1.60 mm respectively. The excitation and emission spectra of PL
F127 was read at 360 and 260 nm, respectively. The excitation and emission spectra for
the pyrene probe was read at 395 and 335 nm, respectively. Data was mathematically
represented using SigmaPlot 11.

Preparation of Pluronic F127 and 5-fluorouracil for in vitro
Experiments
Four PL F127 solutions were prepared from a 10% (w/v) solution of PL F127 in the
media appropriate for the MiaPaCa-2 and PANC-1 cell lines. The 10% (w/v) PL F127
solution was made by dissolving 1 g PL F127 in 10 mL media at 37°C. This solution was
filtered using a Fisherbrand ® 0.22 µm filter (Pittsburg, PA). From this stock, a 5% (w/v)
PL F127 solution was made by diluting 5 mL 10% (w/v) PL F127 with 5 mL of the
appropriate media. From this 5% (w/v) PL F127 solution, 0.004, 0.002, 0.04, 0.02, 4.0,
and 2.0 % (w/v) PL F127 solutions were made. The IC50 dose for each cell line was
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determined to be 80 µM at 48 hrs (Data not shown) and was used in each experiment.
Ten mg of 5-fluorouracil was dissolved in 10 mL of the appropriate media and filtered
with a Fisherbrand® 0.22 µm filter. From this stock solution, a 320 µM solution was
made. A 160 µM 5-fluorouracil solution was made from the 320 µM 5-fluorurasil
solution by dilution of 5 mL with 5 mL of the appropriate media.

Cell Culture and Plating
MiaPaCa-2 cells were grown in DMEM/high glucose supplemented with 4.00 mM Lglutamine, 4500 mg/L glucose, sodium pyruvate, 50 mL FBS, and 5 mL penicillinstreptomycin antibiotics. Cells were incubated at 37°C with an environment containing
5% CO2. Likewise, PANC-1 cells were grown in DMEM supplemented with 4mM Lglutamine, 50 mL FBS, and 5 mL penicillin-streptomycin antibiotics. Similarly, these
cells were incubated at 37°C with an environment containing 5% CO2. Each cell line was
seeded by a different person and did not account for cell doubling time: for the cell
viability experiments using MiaPaCa-2, approximately 2000 cells were seeded using a
standard from 0 to 6000 cells and for cell viability experiments using PANC1,
approximately 1000 cells were seeded using a standard from 0 to 3000 cells.

Cell Viability Analysis
Cell viability experiments were performed using the alamarBlue® assay and analyzed
using a Bio-Tek FLx800 multi-detection microplate reader with the KC4 analysis
program, (version 3.4). Plates were read at excitation and emission wavelengths of 530
and 590 nm, respectively. Cells for each cell viability experiment were seeded in 96-well
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culture plates supplied by Corning (Corning, NY) and allowed to incubate 2 days prior to
the addition of drug. For each cell line, 3 separate plates were used indicating a 24, 48,
and 72 hr time point at which cells would be analyzed. Six or more wells were given to
each particular type of treatment. Separate plates treated for 48 hrs were also prepared for
purposes of phase contrast imaging using the Olympus 1X71 microscope and Spot
camera analysis program, version 4.6. Aside from wells dedicated to the control and 5flurouracil treatment alone, treatment layout consisted of PL F127 concentrations 0.001,
0.01, 1, and 2.5% (w/v) PL F127 both with and without 80 µM 5-fluorouracil. Total well
volumes were 100 µL. Upon day of analysis, 10 µL alamarBlue® was added and allowed
to incubate for 5 hrs prior to reading.

Cell Cycle Analysis
Cell cycle was monitored using a FACSCalibur flow cytometer and BD Cell Quest™
Pro, version 4.01. Each cell line was analyzed using a different plating method. For the
MiaPaCa-2 cell line, approximately 50,000 cells were seeded in four vented 25 cm2 tissue
culture flasks supplied by BD Falcon (Dickinson, UK). Likewise, 100,000 PANC-1 cells
were seeded in a 12-well culture plates from BD Falcon. After a 48hr incubation period,
cells were treated. Aside from the control and 5-fluorouracil flasks, cells were treated
with 2.5% (w/v) PL F127 with or without 5-flourouracil. Separate flasks were prepared
for readings at the time points 24, 48, and 72 hrs. Upon day of analysis, cells and their
supernatant were centrifuged at 1500 rpm for 5 min and resuspended in 200 µL 10 mM
PBS filtered through a 0.22 µm filter. 1.8 mL ice cold 70% ethanol was added dropwise
while vortexing samples. Samples were stored on ice for 30 min and then in a -20°C
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freezer until analyzed. Before analysis, samples were centrifuged at 1500 rpm for 5 min
and resuspended in 400 µL filtered PBS. Ten mg RNase was dissolved in 10 mL
ultrapure water and 50 µL of this RNase solution was added to each sample. Likewise, 50
µL PI was added to each sample and was prepared by dissolving 4 mg PI in 10 mL
ultrapure water. Samples were allowed to incubate at 37°C for 30 min before being
analyzed by flow cytometry.
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CHAPTER 3
RESULTS

Characterization of Pluronic F127
The chemical composition and temperature determines the aggregation properties of
PL F127 [18-20]. To determine these aggregation properties at physiological conditions,
fluorescence measurements were performed using a hydrophobic fluorescent pyrene
probe. The fluorescence of the pyrene probe depends on the microenvironment of its
surroundings [72]. Using this characteristic, a pyrene probe was inserted in several
concentrations of PL F127 in order to determine its phase characteristics. Figure 3 shows
these changes in fluorescence for both 25 and 37 °C at λex = 335 nm.
The data in Figure 3 was represented in two ways. First, the integrated areas from I350I500 were calculated and plotted as a factor of PL F127 concentration (A). Since
fluorescence intensity of the hydrophobic pyrene probe depends on its thermodynamic
stability in solution, the intensity is higher at micellar concentrations of PL F127.
Specifically, there are phase changes leading to the formation of PL micelles at higher
concentrations of PL F127. As a result, the hydrophobic pyrene probe is capable of
becoming stabilized in the hydrophobic core of the micelle. This stabilization is
represented by higher emission intensities, and greater areas under the emission curves.
The inflection point in the sigmoid curve represents the unimer to micelle phase change
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of PL F127. This cmc value is around 0.01-0.1 % PL F127 (w/v) at 37 °C and around
0.1-1.0 % PL F127 (w/v) at 25°C.
The data in Figure 3 was also represented as pyrene I372/I385 ratios (B). These ratios
have been shown to correlate with the microenvironment of the pyrene [73-74].
Depending on the solvent polarity, the fluorescent intensity of two bands at 372 and 385
either increase or decrease. Specifically, as the hydrophobic pyrene probe is stabilized in
a more hydrophobic environment, the I385 increases. Thus, at higher micellar
concentrations of PL F127, the pyrene probe is stabilized in the hydrophobic core of the
PL F127 micelle, increasing the probe's I385, and decreasing the I372/I385 ratio. Again, the
inflection point in the sigmoid curve represents the unimer to micelle phase change of PL
F127. In this representation of the data, the cmc occurs around 0.01-0.1% (w/v) at 37 °C
and around 0.1-1.0 % (w/v) PL F127 at 25 °C.

Figure 3. Changes in pyrene fluorescence at various PL F127 concentrations. (A):
changes in area under pyrene fluorescence (I350-I500). (B): Changes in the ratio of the first
and third pyrene fluorescent intensity peaks (I372/I385). Fluorescence intensity was
monitored at λex = 335 nm.
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Evaluation of Cell Viability
Since the pro-apoptotic effects of PL are observed at different molecular formations
depending on their chemical structure, it was important to first observe the effect of PL
F127 at concentrations above and below the cmc, with and without of 5FU. Since the
cmc of PL F127 was centered around 0.1% (w/v) under physiological temperatures,
concentrations of 0.001, 0.01, 1.0, and 2.5% (w/v) PL F127 were used to fulfill this
purpose in the following experiments. In vitro cell viability experiments using two
pancreatic adenocarcinoma cell lines were performed to test for synergism between PL
F127 and 5FU. The MiaPaCa-2 and PANC-1 cell lines selected were based on their
sensitivity and resistivity towards current chemotherapy treatments. PL F127 was used as
a hydrophilic surfactant towards drug solubilization of 5FU. The IC50 concentration of 80
µM 5FU at 48 hrs was used as a comparison. Any synergistic effect would be compared
to that of the control and 5FU alone. These experiments were performed using
alamarBlue® (Invitrogen).
Figure 4 represents the results from the cell viability experiments performed on the
more sensitive cell line MiaPaCa-2. The use of 80 µM 5FU significantly lowered the cell
viability of MiaPaCa-2 by 40% as compared to the control (p < 0.001). The effect of PL
F127 alone on MiaPaCa-2 cell viability largely relied on the concentrations above 0.01%
(w/v) and did not show any significant influence at the lowered conentrations. For
instance, the use of 2.5% PL significantly reduced cell viability by 30% as compared to
the control (p < 0.001). When both 80 µM 5FU and concentrations of PL F127 above
0.01% (w/v) were used, there was an enhanced cytotoxic effect towards as compared to
the control and 80 µM 5FU alone. For instance, the use of 80 µM 5FU with 1% PL F127
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led to a nearly 60% decrease in cell viability as compared to the control (p < 0.05);
making the combination more cytotoxic by nearly 20% as compared to the use of 5FU
alone. Likewise, the use of 80 µM 5FU with 2.5% (w/v) PL F127 led to a 70% decrease
in cell viability as compared to the control (p < 0.001); making the combination more
cytotoxic by nearly 30% as compared to the use of 5FU alone. We observed that the use
of 0.01% PL F127 and 80 µM 5FU had no significant effect on cell viability. Even in the
presence of 5FU, the effect was not significantly different as compared to the control.
Furthermore, this treatment led to a 50% enhancement of cell viability as compared to the
use of 5FU alone (p < 0.001).

MiaPaCa-2 48hr Treatm ent Sum m ary
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0.001% 0.01% PL
PL/5FU

0.01%
PL/5FU
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2.5% PL

2.5%
PL/5FU

Figure 4. 48hr cell viability for MiaPaCa-2 treated with 5FU and PL F127 at concentrations
below and above the cmc. (Mean ± S.D., n=18. *** and * represent p < 0.001 and p < 0.05
respectively)

Figure 5 represents the results from the cell viability experiments performed on the
more resistant pancreatic adenocarcinoma PANC-1 cell line. For purposes of simplicicity,
not all significant differences are shown on the chart (See Appendix B for full summary).
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Overall, the addition of PL F127 above and below 0.01% (w/v) did not significantly
enhance cell cytotoxicity as compared to the control or the effect of 5FU alone. However,
certain trends were similar to those seen from the MiaPaCa-2 cell line. The use of 80 µM
5FU significantly lowered the cell viability of PANC-1 as compared to the control by
more than 50% (p < 0.001). This effect was maintained when combined with PL F127 (p
< 0.001 for each concentration of PL). For instance, the use of 80 µM 5FU with 0.001,
0.01, 1, and 2.5% PL F127 led to a 50%, 50%, 30%, and 60% decrease in cell viability as
compared to the control, respectively. The addition of PL F127 at concentrations above
and below the cmc to 5FU, however, did not significantly enhance an effect on viability
as compared to the use of 5FU alone.
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Figure 5. 48hr cell viability for PANC-1 treated with 5FU and PL F127 at concentrations below
and above the cmc. (Mean ± S.D., n=18. *** represents p < 0.001)

Each cell line used in the cell viability experiments showed a similar response
towards 80 µM 5FU. This effect was significantly maintained when combined with PL
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F127 except at 0.01% for MiaPaCa-2 where the viability was similar to the control. Both
cell lines also showed similar responses to all concentrations of PL F127 when used
alone. Furthermore, both cell lines showed a significant decrease in viability in response
to 2.5% PL alone as compared to the control (p < 0.001).

Microscopy of Cell Viability Data
Phase contrast images were taken at 48 hrs, under the same experimental conditions
from the cell viability experiments, to visually monitor the effect of PL F127 and 5FU on
the cell viability. Figure 6 shows a representative collection of MiaPaCa-2 phase contrast
images. There is qualitative agreement between the phase contrast images of MiaPaCa-2
and its cell viability data. As compared to the control, cells treated with 80 µM 5FU show
decreased number. Furthermore, cells treated with both 80 µM 5FU and concentrations
1% and 2.5% PL F127 show an enhanced effect on cell viability as compared to the use
of 5FU alone. Likewise, phase contrast images of PANC-1 under the same conditions as
those in the cell viability experiments show no obvious differences in cell number (Figure
7).

29

Control

1% PL + 80 µM 5FU

80 µM 5FU

2.5% PL

1% PL

2.5% PL + 80 µM 5FU

Figure 6. 48 hour phase contrast images of MiaPaCa-2 cell lines treated with PL F127 and 5FU.
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1% PL
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Figure 7. 48 hour phase contrast images of PANC-1 cell lines treated with PL F127 and 5FU.
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Evaluation of Cell Cycle
Cell cycle is regulated through various mechanisms that are dependent on both
internal and external stimuli. These alterations in cell cycle can be monitored via flow
cytometry. By measuring cell DNA content, flow cytometry is capable of measuring cell
percentages in particular phases of their cell cycle. From the cell viability data there
appears to be an enhanced effect on viability in the treatment of MiaPaCa-2 cells with
5FU and concentrations of PL F127 above the cmc as compared to the use of 5FU
treatment alone. Therefore, any effect observed on cell cycle from 5FU should be
enhanced in combination with micellar concentrations of PL F127. In these experiments,
propidium iodide was used to measure the percentages of cells in particular phase of the
cell cycle when treated with 5FU and micellar concentrations of PL F127 for 48 hrs. Both
MiaPaCa-2 and PANC-1 cell lines were used using the same experimental conditions as
those in the cell viability studies. Along with 80 µM 5FU, only 2.5% PL F127 was used
to observe any effect on cell cycle since the effect on cell viability was greatest at this
concentration.
Table 1 shows the summary of cell cycle data for MiaPaCa-2. Cells that are sub G1
account for cells that are either going through apoptosis, necrosis, or as cell debris. From
the data in Table 1, it can be seen that 5FU and 2.5% PL alone did not significantly
induce cells into cell death as compared to the control. However, the combination
treatment of 2.5% PL F127 and 5FU significantly induced cell death as compared to the
control. Furthermore, the percentages of cells induced into cell death due to the
combination of 2.5% PL F127 and 5FU was significantly higher compared to the
percentages of cells killed from PL F127 alone. Maturing cells that await another round
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of mitosis are kept in the G1 phase of the cell cycle. As seen from Table 1, there were
significantly less cells found in this phase of the cell cycle after treated with 5FU alone
and the combination of 2.5% PL F127 and 5FU. As compared to the control, since there
were significantly higher percentages of dead cells due to the combination treatment of
2.5% Pl F127 and 5FU, it would be expected that less cells would also be able to go
through another round of cell cycle. However, the use of 5FU alone did not significantly
increases the percentages of dead cells as compared to the control. Overall, there were no
significantly increased percentages of cells, indicating cell arrest, in any of the phases of
the cell cycle, making it not possible to characterize the effect of PL F127 on cell cycle.
In PANC-1 cells, there were no significantly increased or decreased percentages of cells
in any of the phases of the cell cycle as compared to the control and the various
treatments (Table 2).
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Table 1. Summary of cell cycle data for MiaPaCa-2. Values are expressed as percentages
of cells in a particular phase of the cell cycle (Mean, n=3. Superscript number pairs show
values that are significantly different from each other, p < 0.05).

5.07
3, 4
61.98
8.16
18.46

80 uM
5FU
27.06
4
29.78
18.85
13.6

2.5% PL
F127
2
14.55
48.54
6.95
16.8

2.5% PL F127
+ 80 uM 5FU
1, 2
45.50
3
25.54
10.5
11.81

6.28

11.28

13.39

6.92

Control
Sub G1
G1
S
G2/M
Polyploidic

1

Table 2. Summary of cell cycle data for PANC-1. Values are expressed as percentages of
cells in a particular phase of the cell cycle (Mean, n=3. Superscript number pairs show
values that are significantly different from each other, p < 0.05).

4.14
57.12
12.74
20.98

80 uM
5FU
31.43
15.61
29.32
18.77

2.5% PL
F127
40.69
28.16
9.27
17.85

2.5% PL F127
+ 80 uM 5FU
40.07
31.52
10.7
14.88

4.93

4.9

4.05

2.91

Control
Sub G1
G1
S
G2/M
Polyploidic
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CHAPTER 4
DISCUSSION

Explaining Cytotoxicity through Phenotype and Genotype
There are several contributing factors that may lead to the varying degrees of drug
resistance and cell propagation. For instance, cell adhesion properties, affect tumor
growth, metabolism, and metastatic potential [44, 46]. The aggressiveness on the other
hand may be contributed to the cancer's invasive and angiogenic potential [44, 75-76].
However, correlating such phenotypic characteristics to the chemosensitivity of the
individual cell lines used in this study requires a more detailed analysis. Unfortunately,
there is currently a lack of research that consistently correlates genotype to phenotype
and cell behavior of pancreatic cancer cell lines [44-46].
The genotype defines a particular type of pancreatic cancer cell line. However,
research has shown that the genotype, phenotype, and cell behavior can vary between the
same cell line derived from an organ system [44-46]. For instance, the time at which it
takes for the population of cells to double their current number varies in between studies:
18-40 hours for MiaPaCa-2 and 25 to 52 hours for PANC-1 [45-46, 77-78]. Doubling
time depends on several criteria such as the availability of growth factors, which is
inadvertently related to the degree of cell compaction [45]. Although doubling time
depends on initial seeding population, doubling time variability between studies can be
contributed to several other factors. For example, culture conditions, passage duration,
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and passage time increase probability of genetic drift from the primary cell line source,
leading to changes in cellular morphology, genetic expression, phenotype, and overall
cell behavior [44, 79-81]. In this study, passages from two to five were used in order
minimize these experimental and technical errors in cell culture.
Cell behavior and response to chemotherapeutics has also been shown to depend on
the integrity of culture conditions [80]. In this study, the response of both the cell cultures
to 5FU was relative to their IC50. This IC50 value was 80 µM and was the same for each
cell line. However, the reported IC50 dose varies between several studies which in
themselves vary from each other. For example, some studies have determined IC50 doses
ranging from 4 to 38 uM 5FU for MiaPaCa-2 cells [45, 82-83]. In our experiments, we
have determined the IC50 dose to be double these concentrations. These differences in
chemosensitivity are likely do to the variations in methodology between studies. The
question then becomes from what cell culture method is the cell behavior and
chemotherapy responsiveness truly representative of each cell line.
Duxbury and coworkers used the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay in order to determine the IC50 dose of 5FU in both MiaPaCa-2 and
PANC-1 after 96 hrs [82]. Using these methods, they determined the IC50 to be 38 µM
for MiaPaCa-2 and 62 µM for PANC-1. The MTT assay works in a similar manner as
alamarBlue® in that it measures cell viability via components of cellular respiration.
Normally, MTT is a soluble dye that is capable of passing through cellular membranes,
including the mitochondria. However, MTT becomes insoluble after being reduced
through the action of dehydrogenases and their cofactors [84]. After the insoluble product
is solubilized, its optical density can be measured, which is proportional to the amount of
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viable cells. However, and unlike alamarBlue®, by becoming reduced in the
mitochondria, it puts an end to the flow of electrons in the electron transport chain [85].
Both this and the presence of the insoluble byproduct later induce cell death.
This extent of treatment prior to analysis may explain the variation with our own
experiments and with the studies of others. For instance, it is hypothesized that longer
incubation periods call for higher doses to account for the proliferation of cells over a 96
hour period. If this were the case, researchers would run the risk of calibrating the IC50 to
the chemoresistant cells. In other words, at high doses of chemotherapeutic, sensitive
cells are killed, leaving behind the more resistant strain behind. The dose is then
calibrated so that 50% of these cells, now resistant, are viable as compared to the control
after 96 hours. On the other hand, the effect of smaller doses over a 96 hour period may
be hidden by the degree of proliferation. Therefore, seeding density may also cause
variation in the observed IC50. Still, these hypotheses appear to somewhat contradict our
own data since we used shorter time points but still found the IC50 of 5FU to be higher
than in this particular study. It does not however entirely exclude the possibility that the
difference in the IC50 concentrations is due to the inadvertent selection of chemoresistant
cells.
Shi and his colleagues, on the other hand used a Sulforhodamine B (SRB) assay in
order to determine the IC50 for MiaPaCa-2. Using a 72 hour incubation period, they found
the IC50 of 5FU for MiaPaCa-2 to be around 5 µM [83]. This particular assay works in an
entirely different manner than alamarBlue® and MTT; instead of measuring viability
through cellular respiration, SRB measures it through the protein content. Specifically,
the SRB dye binds electrostatically and pH dependent wise to the basic amino acids of
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cellular proteins [86]. By extracting and dissolving these dyed proteins, it is possible to
measure their optical activity and correlate its degree to cell viability. It is until this stage
of extraction that the SRB assay remains nondestructive.
The IC50 for 5FU in MiaPaCa-2 that was determined and used in our study was 16
times more concentrated than that from Shi's studies. Likewise, Duxbury's studies
determined an IC50 for 5FU in MiaPaCa-2 that was nearly 8 times more concentrated than
the IC50 in Shi's study. A few methodological factors may be contributing to such
variation amongst the literature and our own data. First, SRB depends on protein integrity
and native structure [86]. However, a key feature of 5FU is its ability to cause
modifications in tRNA and rRNA [87-92]. As a result, the availability of native protein
structures with native basic amino acids can be expected to be altered in some way. It is
therefore reasonable to consider that the SRB assay shows altered cell viability because
of its misrepresented affinity to the denatured proteins. Second, each study used different
seeding densities, allowing for various degrees of cellular responses to growth factors and
other extracellular interactions [45]. Overall, the variation seen in the IC50 for 5FU in
both MiaPaCa-2 and PANC-1 could depend on several factors, making it imperative that
any conclusions in this work are kept relative to these specific experimental conditions.

Cell Viability Data
The cytotoxicity of 5FU and PL F127 on MiaPaCa-2 and PANC-1 was assessed using
the alamarBlue® cell viability assay. This dye measures cell viability via measurement of
cellular respiration. Normally, this dye is blue but becomes pink after being reduced
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during the final stages of the electron transport chain [85]. This color change indicates the
activation of a fluorescent probe that is detectable at 530/590 nm.
Membrane and protein complexes in the mitochondria are known targets of PLs [18,
21, 28-29, 58-59]. Even though there have not been any definitive studies that
characterize the migration of PL F127 within the cell, it is still amphiphilic and may
therefore have possible internal cell structure targets. Given the scenario where PL F127
actually migrates to the mitochondria, it may be capable of altering mitochondrial
membrane integrity and the conformations of protein complexes involved in cellular
respiration. Since alamarBlue® depends on the integrity of the electron transport chain,
the response from the dye would be affected; less dye would be reduced and become
fluorescent, indicating viable cells. Although the cells would indeed be in a state of
stress, their lack of viability as shown from the dye may not be entirely representative of
their overall viability. In summary, PL F127 would distort the results shown from the
alamarBlue® cell viability assay. However, without conclusive data showing the
migration abilities of PL F127 in MiaPaCa-2 and PANC-1, these suspicions can not be
fully addressed.

Cell Cycle Data
The main purpose of flow cytometry in this study was to characterize the effects seen
from the cell viability data in terms of the phases of the cell cycle. However, cell cycle
analysis using flow cytometry showed no significant differences in the phases of the cell
cycle in both MiaPaCa-2 and PANC1 as compared to the control. It was expected that
PANC-1 would show little change in its cell cycle, as compared to the control, since it
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showed resistance to PL F127 in the viability experiments. However, these results appear
contradictory when in comparison to MiaPaCa-2, where as compared to the control and
the use of 5FU alone, there were significant changes in viability due to micellar
concentrations of PL F127. Most importantly, where significant changes in cell viability
due to 5FU alone as compared to the control were observed from the cell viability data,
there was no significant effect on cell cycle. These observations were surprising for a few
reasons. Therefore, in the following sections we will describe what was expected from
these experiments and critically analyze the data for trends that may help future works
that use similar experimental methods. However, the majority of these descriptions will
include insignificant data from the flow cytometry experiments.
Before we begin the discussion, it is important to first mention that although it is
based on statistically insignificant trends, it still largely relies on the integrity of the
mechanics of cell cycle checkpoints. These checkpoints will be able to tell us in which
phases of the cell cycle the cells are arrested, if not killed or poly-ploidic. However, it
may be the machinery of the checkpoint itself that is affected in each cell line,
contributing to its cancerous characteristics, and concealing the cell cycle arrest we may
expect. As stated previously, one of the characteristic mutations in pancreatic
adenocarcinoma cell lines are in p53. This tumor suppressor is not only responsible for
cell cycle regulation but is also a component of the G1 to S phase cell cycle checkpoint
[93-94]. Since this tumor suppressor is mutated in both MiaPaCa-2 and PANC-1, it may
contribute to the insufficiency of cell cycle arrest. However, complete control of this
checkpoint is not lost due to checkpoint mechanisms independent of p53 [95].
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Furthermore, p53 is by no means the only checkpoint component throughout the other
phase checkpoints of the cell cycle.
Beginning this discussion with the control, the cell cycle data for the MiaPaCa-2 and
PANC-1 showed that ~4 to 5% of the cells were sub G1, an area often indicating
fragmented DNA from dead or dying cells. Likewise, each cell line had around 60% of
its cells in the G1 phase. Since the majority of the cells are in this phase indicating the end
of mitosis and cell division, we may deduce that the cells have received signals to alter
cell cycle. This is a common response in molecular cell biology due to significant cell-tocell contact [1, 96-97]. A study using identical staining and analysis time points showed
that nearly 50% of cells in each cell line were in the G1 phase [45]. Using these
parameters they also measured the effect on cell cycle using common chemotherapeutics,
including 5FU. From these experiments they were able to discern cells in apoptotic
regions. In comparison to our data and methods, we may conclude that the high
percentages of cells observed in the G1 phase in our cell lines may not entirely indicate
significant influence in cell proliferation. Furthermore, we should be able to locate
regions of significant changes in cell cycle. Other indicators of cell cycle progression are
the S and G2/M phases of the cell cycle. The percentages of cells in these phases were
similar in each cell line and also similar to previous studies [45].
Next, we look at the effects of 5FU on cell cycle for MiaPaCa-2 and PANC-1. The
treatment with 5FU in both cell lines was expected to yield different results from the
control but also from each other due to individual chemosensitivity. [45, 71, 98].
Nevertheless, significantly increased percentages of cells in the S phase, indicating
activation of a cell cycle checkpoint and induction of cell arrest, were expected since 5FU
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affects both DNA and RNA fidelity. First, there was nearly five times the percentage of
cells in the sub G1 phase in MiaPaCa-2 as compared to the control. In PANC-1, there was
nearly eight times the percentage of cells in the sub G1 phase as compared to the control.
Looking at the percentages of cells in the G1 phase in MiaPaCa-2 and PANC-1 showed a
decreased percentage of nearly two and four times, respectively, as compared to the
control. These numbers correlated to the percentages seen in the S phase of each cell line:
nearly 2-3 times more than the control. MiaPaCa-2 cells also seemed to be more
susceptible to poly-ploidy than PANC-1 as seen from the data. Since 5FU affects both
DNA and RNA fidelity, critical structural and signaling components during mitosis could
have been affected.
Next, the effects of 2.5% PL F127 alone will be discussed. From the cell viability data
of both cell lines, 2.5% PL F127 was able to exert a cytotoxic effect similar to the degree
seen by 5FU alone. In an attempt to explain this effect first through the cell cycle of
MiaPaCa-2, we found results similar to that of the control; the difference being that
treatment with 2.5% PL F127 caused an increase in the percentage of cells found in sub
G1 and the poly-ploidic region. In comparison to the control, MiaPaCa-2 had nearly the
same ratios of cell percentages passing from G1 to S to the G2/M. However, these
percentages were lower after the PL F127 treatment due to the percentages found in sub
G1 and the poly-ploidic region. Since the ratios of cells passing through the normal
phases of the cell cycle were similar to the control, this data would suggest that those
cells affected adversely by PL F127 were affected so by the influence on the structural
components involved in the mechanical separation of cells. Due to PL F127s
composition, we suspect that this effect is likely to cause perturbations of the cell
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membrane and not from intracellular interactions [17, 23, 99-100]. However, the
treatment of cells with PL F127 does not comparatively have as great of an effect on
percentages in sub G1 as does 5FU alone.
When comparing the results of PANC-1 cells treated with 2.5% PL F127 with its
control, we saw that the ratios of cells going from the G1 to S to the G2/M phase was not
proportionate to those seen from the control. Furthermore, we saw that there were
noticeably more cells in the sub G1 phase of the cell cycle. This makes these percentages
difficult to interpret for a few reasons. First, we saw that percentage of cells in the G1
phase was lower than the percentage found in the control. This would imply cell arrest in
the G2/M phase of the cell cycle. However, when we compare the G2/M of the PL F127
treated cells with the control, we see no noticeable differences between the two.
Additionally, we can not explain the cytotoxic effect of PL F127 based on its ability to
induce poly-ploidy since the percentages of cells in this region was nearly the same to
that of the control. It is true that the majority of these descriptions of our cell cycle data
use insignificant data. However, without any noticeable trends, and without further
analysis, it can only be concluded that PANC-1 responds adversely to PL F127 in a
manner that avoids detection using these methods.
The fact that 40% of the cells are counted as debris is of concern in regards to the
ability of flow cytometry to accurately measure cell cycle. This is because at such high
degrees of cell death, remaining cells are possibly those selected based on their tendency
to be resistant and do not represent the true sample group. Degree of cell death can be
contributed to a few factors: dose and time of treatment. However, since we wanted to
examine the cytotoxic effect at a selected dose, the alternative would be to choose a
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shorter time points at which to analyze the samples. This way, we are able to catch the
process of cell cycle prior to mass cell death. In our experiments, we chose a time point
of 48 hrs before cell cycle analysis. Perhaps a more reasonable time point to analyze the
samples would be before 48 hrs. Being aware of this issue, we have performed
preliminary studies using the time points 6, 12, 18, and 24 hrs (See Appendix). Although
this experiment has only been performed once, it showed that even a 24 hour treatment
may be too late to analyze samples.
Lastly, we compared the effect of combination treatment with the individual effect of
2.5% PL F127 and 5FU. In MiaPaCa-2, we saw that there was a significantly increased
percentage of cells that were sub G1 as compared to the control (p <0.01) and the use of
PL F127 alone (p<0.05). We therefore need to identify either the presence or absence of
cooperation between PL F127 and 5FU. In other words, do PL F127 and 5FU display
synergism in their cytotoxicity?
The additive effect of 5FU and PL F127 towards cell percentages in sub G1 would
imply that we are not observing an entirely new effect in MiaPaCa-2. Rather, we are
observing the individual effect of both PL F127 and 5FU. However, the effect on polyploidy disappears. It may be reasonable to conclude that the absence of the additive effect
on poly-ploidy is due to alternative pathways that the combination treatment uses.
Nevertheless, it must be pointed out that nearly half of the cells are counted as debris. On
the other hand, PANC-1 does not show an additive effect on cell percentages in sub G1;
only 40% are counted as debris. Either the combination treatment protects 60% of the
cells or the additive cytotoxic effect of 70% (and likely more if we are considering that
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we are observing the cell cycle of the more resistant cells after the PL F127 treatment)
selects the more resistant cells at which only 40% are counted as debris.

Conclusions
In this study we found that there was enhanced cytotoxicity of 5FU when used in
combination with PL F127 at concentrations above the cmc. These effects were only seen
in the chemosensitive cell line MiaPaCa-2 and not in the chemoresistant PANC-1 cell
line. Furthermore, at very high concentrations of PL F127, there is significant cell
cytotoxicity in both cell lines. From the cell viability and microscopy studies, this data
would suggest that the combined treatment using 5FU and PL F127 at concentrations
above the cmc for more sensitive pancreatic cancer cell lines is more effective than
treatment with 5FU alone. However, any perturbations in cell viability could not be
identified as a synergistic or additive.
Preliminary characterization of the two cell lines after treatment using flow cytometry
did not significantly show any changes in cell cycle. These results are believed to be due
to methodological errors in cell harvesting and in the flow cytometry instrument settings.
However, the trends observed from the cell cycle studies do agree with the data seen from
the cell viability experiments.

Future Studies
The purpose of this study was to observe the effect of 5FU in combination with PL
F127 and correlate any enhanced cytotoxicity to synergism. However, it did not explore
means to characterize the effect of 5FU with PL F127. More specifically, the mechanism
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at which 5FU acts as an antimetabolite has already been well characterized [68-69].
However, it is still unknown what role PL F127 plays in cell cytotoxicity. The future
studies would therefore address the presence of synergism.
The first question would be the structural characteristics of the 5FU and PL F127
mixture. For instance, where is 5FU partitioned when concentrations of PL F127 are
above the cmc? Furthermore, is the dose of 5FU delivered to the cells enhanced when
using concentrations of PL F127 above the cmc? One method in which this could be
explored would be through use of solid dispersion. Although it is true that 5FU is
relatively hydrophilic and water soluble, it is still theoretically capable of being dispersed
in between the hydrophilic corona and hydrophobic core of the PL micelle [17]. For
example, Kwon and others used solid dispersion to encapsulate genistein in PL F127
micelles. After filtering to remove undissolved genistein, these micelles were freeze dried
and weighed to measure loading capacity [21]. Micelle stability and cargo release were
measured using a dialysis bag and HPLC. Using 5FU in the place of genistein, we could
measure loading capacity and release to better identify the role of PL F127 in our study.
The second area of interest would be to identify the cytotoxicy of PL F127 alone. For
instance, why do we see that at 2.5% PL there is a cytotoxic effect nearly equal to that of
5FU alone in both cell lines? At concentrations of PL F127 high above the cmc, the
micelles begin to reassemble and aggregate into gels [100]. Furthermore, the ability to
form gels increases with increasing temperature [101-104]. Therefore one route could be
to explore the possibility that at these high concentrations of PL F127, the extracellular
environment alters the viscosity enough to disturb the kinetics involved in nutrient
absorption and metabolite product secretion, inadvertently creating a state of starvation.
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For reasonss mentioned previously, these unfavorable growth conditions would cause
perturbations in phases of the cell cycle which could be monitored via flow cytometry.
However, this does not reject the possibility that PL F127 micelles mediate a direct
cytotoxic effect via altering membrane microviscosity or through adverse signaling
cascades.
In order to differentiate the cytotoxic effect of PL F127 as either indirect or direct
would require a means of locating PL F127 throughout the entire cell. One way to
characterize the location of PL F127 when using concentrations high above the cmc
would be to use fluorescence resonance energy transfer (FRET). For instance, when using
a modified PL molecule as the donor and Cholera toxin B as the acceptor probe,
Batrakova and coworkers observed an exchange of fluorescence localized on lipid rafts
believed to be associated with Pgp pumps [17]. Using similar methods, it is believed we
could create fluorescent donor and acceptor pairs for the lipids at various locations within
the cell, i.e. the cell membrane or mitochondria. Although this will likely be an
exhaustive study, it would allow us to localize the PL F127 and correlate its position with
potential cytotoxic capabilities; for instance, localization in the mitochondria may be
correlated with mitochondrial membrane microviscosity changes and thus perturbations
in mitochondrial mediated apoptotic signaling.
After examining more qualitative means to better understand our data, it would be
interesting to explore experimental conditions that take advantage of the physical
characteristics of PLs. For example, there have not been any studies that take advantage
of PL F127's ability to compartmentalize and deliver hydrophobic drugs in either
MiaPaCa-2 or PANC-1. Mixtures of PLs also benefit pharmacokinetics and
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pharmacodynamics by improving lipophilicity towards target cells [17, 22]. Knowing
this, we could increase micelle hydrophobicity content through addition of more
hydrophobic PLs such as L31, P85, and L61. As a result of the increased hydrophobicity
content, cell membrane affinity requirements are met and drug delivery becomes more
efficient.
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APPENDIX A
ONE-WAY ANOVA AND TUKEY-KRAMER MULTIPLE COMPARISON
TESTS OF MIAPACA-2 CELL VIABILITY DATA

Control vs 80 uM 5FU
Control vs 0.001% PL
Control vs 0.001% PL/5FU
Control vs 0.01% PL
Control vs 0.01% PL/5FU
Control vs 1% PL
Control vs 1% PL/5FU
Control vs 2.5% PL
Control vs 2.5% PL/5FU
80 uM 5FU vs 0.001% PL
80 uM 5FU vs 0.001% PL/5FU
80 uM 5FU vs 0.01% PL
80 uM 5FU vs 0.01% PL/5FU
80 uM 5FU vs 1% PL
80 uM 5FU vs 1% PL/5FU
80 uM 5FU vs 2.5% PL
80 uM 5FU vs 2.5% PL/5FU
0.001% PL vs 0.001% PL/5FU
0.001% PL vs 0.01% PL
0.001% PL vs 0.01% PL/5FU
0.001% PL vs 1% PL
0.001% PL vs 1% PL/5FU
0.001% PL vs 2.5% PL
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*** P<0.001
ns P>0.05
*** P<0.001
** P<0.01
* P<0.05
ns P>0.05
*** P<0.001
*** P<0.001
*** P<0.001
*** P<0.001
ns P>0.05
*** P<0.001
*** P<0.001
*** P<0.001
* P<0.05
ns P>0.05
*** P<0.001
** P<0.01
** P<0.01
** P<0.01
ns P>0.05
*** P<0.001
** P<0.01

0.001% PL vs 2.5% PL/5FU
0.001% PL/5FU vs 0.01% PL
0.001% PL/5FU vs 0.01% PL/5FU
0.001% PL/5FU vs 1% PL
0.001% PL/5FU vs 1% PL/5FU
0.001% PL/5FU vs 2.5% PL
0.001% PL/5FU vs 2.5% PL/5FU
0.01% PL vs 0.01% PL/5FU
0.01% PL vs 1% PL
0.01% PL vs 1% PL/5FU
0.01% PL vs 2.5% PL
0.01% PL vs 2.5% PL/5FU
0.01% PL/5FU vs 1% PL
0.01% PL/5FU vs 1% PL/5FU
0.01% PL/5FU vs 2.5% PL
0.01% PL/5FU vs 2.5% PL/5FU
1% PL vs 1% PL/5FU
1% PL vs 2.5% PL
1% PL vs 2.5% PL/5FU
1% PL/5FU vs 2.5% PL
1% PL/5FU vs 2.5% PL/5FU
2.5% PL vs 2.5% PL/5FU

*** P<0.001
*** P<0.001
*** P<0.001
*** P<0.001
*** P<0.001
ns P>0.05
*** P<0.001
ns P>0.05
ns P>0.05
*** P<0.001
*** P<0.001
*** P<0.001
ns P>0.05
*** P<0.001
*** P<0.001
*** P<0.001
*** P<0.001
*** P<0.001
*** P<0.001
*** P<0.001
ns P>0.05
*** P<0.001

* represent the degree of significance and ns indicates a non significant comparison.
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APPENDIX B
ONE-WAY ANOVA AND TUKEY-KRAMER MULTIPLE COMPARISON
TESTS OF PANC-1 CELL VIABILITY DATA

Control vs 80 uM 5FU
Control vs 0.001% PL
Control vs 0.001% PL/5FU
Control vs 0.01%PL
Control vs 0.01% PL/5FU
Control vs 1% PL
Control vs 1% PL/5FU
Control vs 2.5% PL
Control vs 2.5% PL/5FU
80 uM 5FU vs 0.001% PL
80 uM 5FU vs 0.001% PL/5FU
80 uM 5FU vs 0.01%PL
80 uM 5FU vs 0.01% PL/5FU
80 uM 5FU vs 1% PL
80 uM 5FU vs 1% PL/5FU
80 uM 5FU vs 2.5% PL
80 uM 5FU vs 2.5% PL/5FU
0.001% PL vs 0.001% PL/5FU
0.001% PL vs 0.01%PL
0.001% PL vs 0.01% PL/5FU
0.001% PL vs 1% PL
0.001% PL vs 1% PL/5FU
0.001% PL vs 2.5% PL
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*** P<0.001
*** P<0.001
*** P<0.001
*** P<0.001
*** P<0.001
** P<0.01
*** P<0.001
*** P<0.001
*** P<0.001
*** P<0.001
ns P>0.05
*** P<0.001
ns P>0.05
*** P<0.001
*** P<0.001
ns P>0.05
ns P>0.05
*** P<0.001
ns P>0.05
*** P<0.001
ns P>0.05
*** P<0.001
*** P<0.001

0.001% PL vs 2.5% PL/5FU
0.001% PL/5FU vs 0.01%PL
0.001% PL/5FU vs 0.01% PL/5FU
0.001% PL/5FU vs 1% PL
0.001% PL/5FU vs 1% PL/5FU
0.001% PL/5FU vs 2.5% PL
0.001% PL/5FU vs 2.5% PL/5FU
0.01%PL vs 0.01% PL/5FU
0.01%PL vs 1% PL
0.01%PL vs 1% PL/5FU
0.01%PL vs 2.5% PL
0.01%PL vs 2.5% PL/5FU
0.01% PL/5FU vs 1% PL
0.01% PL/5FU vs 1% PL/5FU
0.01% PL/5FU vs 2.5% PL
0.01% PL/5FU vs 2.5% PL/5FU
1% PL vs 1% PL/5FU
1% PL vs 2.5% PL
1% PL vs 2.5% PL/5FU
1% PL/5FU vs 2.5% PL
1% PL/5FU vs 2.5% PL/5FU
2.5% PL vs 2.5% PL/5FU

*** P<0.001
*** P<0.001
ns P>0.05
*** P<0.001
*** P<0.001
ns P>0.05
ns P>0.05
*** P<0.001
ns P>0.05
ns P>0.05
*** P<0.001
*** P<0.001
*** P<0.001
* P<0.05
ns P>0.05
ns P>0.05
*** P<0.001
*** P<0.001
*** P<0.001
* P<0.05
*** P<0.001
ns P>0.05

* represent the degree of significance and ns indicates a non significant comparison.
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APPENDIX C
ONE-WAY ANOVA AND TUKEY-KRAMER MULTIPLE COMPARISON
TESTS OF MIAPACA-2 FLOW CYTOMETRY DATA

Control M1 vs 80 uM 5FU M1
Control M1 vs 2.5% PL M1
Control M1 vs 2.5% PL/5FU M1
Control M2 vs 80 uM 5FU M2
Control M2 vs 2.5% PL M2
Control M2 vs 2.5% PL/5FU M2
Control M3 vs 80 uM 5FU M3
Control M3 vs 2.5% PL M3
Control M3 vs 2.5% PL/5FU M3
Control M4 vs 80 uM 5FU M4
Control M4 vs 2.5% PL M4
Control M4 vs 2.5% PL/5FU M4
Control M5 vs 80 uM 5FU M5
Control M5 vs 2.5% PL M5
Control M5 vs 2.5% PL/5FU M5
80 uM 5FU M1 vs 2.5% PL M1
80uM 5FU M1 vs 2.5% PL/5FU M1
80 uM 5FU M2 vs 2.5% PL M2
80 uM 5FU M2 vs 2.5% PL/5FU M2
80 uM 5FU M3 vs 2.5% PL M3
80 uM 5FU M3 vs 2.5% PL/5FU M3
80 uM 5FU M4 vs 2.5% PL M4
80 uM 5FU M4 vs 2.5% PL/5FU M4
80 uM 5FU M5 vs 2.5% PL M5
80 uM 5FU M5 vs 2.5% PL/5FU M5
2.5% PL M1 vs 2.5% PL/5FU M1
2.5% PL M2 vs 2.5% PL/5FU M2
2.5% PL M3 vs PL/5FU M3
2.5% PL M4 vs 2.5% PL/5FU M4
2.5% PL M5 vs 2.5% PL/5FU M5

ns P>0.05
ns P>0.05
** P<0.01
* P<0.05
ns P>0.05
** P<0.01
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05
* P<0.05
ns P>0.05
ns P>0.05
ns P>0.05
ns P>0.05

* represent degree of significance, ns indicates a non significant comparison, M1
indicates the sub G1 phase, M2 the G1 phase, M3 the S phase, M4 the G2/M phase, and
M5 the poly-ploidic region.
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APPENDIX D
ONE-WAY ANOVA AND TUKEY-KRAMER MULTIPLE COMPARISON
TESTS OF PANC-1 FLOW CYTOMETRY DATA

Control M1 vs 80 uM 5FU M1
Control M1 vs 2.5% PL M1
Control M1 vs 2.5% PL/5FU M1
Control M2 vs 80 uM 5FU M2
Control M2 vs 2.5% PL M2
Control M2 vs 2.5% PL/5FU M2
Control M3 vs 80 uM 5FU M3
Control M3 vs 2.5% PL M3
Control M3 vs 2.5% PL/5FU M3
Control M4 vs 80 uM 5FU M4
Control M4 vs 2.5% PL M4
Control M4 vs 2.5% PL/5FU M4
Control M5 vs 80 uM 5FU M5
Control M5 vs 2.5% PL M5
Control M5 vs 2.5% PL/5FU M5
80 uM 5FU M1 vs 2.5% PL M1
80uM 5FU M1 vs 2.5% PL/5FU M1
80 uM 5FU M2 vs 2.5% PL M2
80 uM 5FU M2 vs 2.5% PL/5FU M2
80 uM 5FU M3 vs 2.5% PL M3
80 uM 5FU M3 vs 2.5% PL/5FU M3
80 uM 5FU M4 vs 2.5% PL M4
80 uM 5FU M4 vs 2.5% PL/5FU M4
80 uM 5FU M5 vs 2.5% PL M5
80 uM 5FU M5 vs 2.5% PL/5FU M5
2.5% PL M1 vs 2.5% PL/5FU M1
2.5% PL M2 vs 2.5% PL/5FU M2
2.5% PL M3 vs PL/5FU M3
2.5% PL M4 vs 2.5% PL/5FU M4
2.5% PL M5 vs 2.5% PL/5FU M5

ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns

P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05
P>0.05

* represent degree of significance, ns indicates a non significant comparison, M1
indicates the sub G1 phase, M2 the G1 phase, M3 the S phase, M4 the G2/M phase, and
M5 the poly-ploidic region.
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APPENDIX E
ANNEXIN V AND PI STAINING FOR DEGREE OF APOPTOSIS
IN PANC-1 CELLS

PANC-1: Degree of Apoptosis Time Study
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Values in chart represent the percentages of cell in a particular state of viability. Courtesy
of Malyn Asuncion of the Nathan Wall lab.
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